Ken Griffin Silverback Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 25,200 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,200

Previous 32,000 21.25%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	N/A	80,262 Added 252.37%	112,065 $0
Q4 2023 Feb 14, 2024	BUY	N/A	20,265 Added 175.64%	31,803 $0
Q3 2023 Nov 14, 2023	SELL	N/A	-208,810 Reduced 94.76%	11,538 $0
Q2 2023 Aug 14, 2023	BUY	N/A	175,572 Added 392.11%	220,348 $0
Q1 2023 May 15, 2023	BUY	N/A	36,479 Added 439.66%	44,776 $0

Q4 2022 Feb 14, 2023	SELL	$0.0 - $6.07 $0 - $541,280	-89,173 Reduced 91.49%	8,297 $0
Q3 2022 Nov 14, 2022	SELL	$3.91 - $5.52 $524,706 - $740,761	-134,196 Reduced 57.93%	97,470 $515,000
Q2 2022 Aug 15, 2022	BUY	$2.9 - $4.44 $105,879 - $162,104	36,510 Added 18.71%	231,666 $982,000
Q1 2022 May 16, 2022	BUY	$3.51 - $6.74 $356,584 - $684,723	101,591 Added 108.58%	195,156 $685,000
Q4 2021 Feb 14, 2022	BUY	$6.03 - $11.67 $115,010 - $222,581	19,073 Added 25.6%	93,565 $623,000
Q3 2021 Nov 15, 2021	BUY	$9.98 - $35.22 $397,643 - $1.4 Million	39,844 Added 115.0%	74,492 $743,000
Q2 2021 Aug 16, 2021	BUY	$24.71 - $44.28 $856,152 - $1.53 Million	34,648 New	34,648 $1.07 Million
Q1 2021 May 17, 2021	SELL	$37.62 - $60.41 $5.2 Million - $8.34 Million	-138,138 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$25.0 - $46.34 $3.45 Million - $6.4 Million	138,138 New	138,138 $6.4 Million

Others Institutions Holding SBTX

# of Institutions

116

Shares Held

47.9M

Call Options Held

442K

Put Options Held

42K

View Full List

About Silverback Therapeutics, Inc.

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

More about SBTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account